Tofacitinib 5mg [Xeljanz] 1 year open-label extension ( DrugBank: Tofacitinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 84 | Sarcoidosis | 1 |
84. Sarcoidosis
Clinical trials : 149 / Drugs : 227 - (DrugBank : 81) / Drug target genes : 82 - Drug target pathways : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03793439 (ClinicalTrials.gov) | May 15, 2019 | 2/1/2019 | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Sarcoidosis, Pulmonary;Sarcoidosis Lung;Sarcoidosis | Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension | Oregon Health and Science University | Pfizer | Recruiting | 18 Years | 89 Years | All | 5 | Phase 1 | United States |